NCT02933697 (AXADIA) is a Phase 3 clinical trial of Apixaban in Atrial Fibrillation, sponsored by Atrial Fibrillation Network.

Who is sponsoring NCT02933697?

NCT02933697 is sponsored by Atrial Fibrillation Network.

What drugs are being tested in NCT02933697?

Interventions in NCT02933697: Apixaban, Phenprocoumon.

What condition does NCT02933697 study?

NCT02933697 studies Atrial Fibrillation, End-stage Kidney Disease.

Is NCT02933697 still recruiting?

NCT02933697 is currently completed. Last updated 27 September 2022.

Last reviewed 2022-09-27 · How we verify

NCT02933697: AXADIA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)

Completed Phase 3 Last updated 27 September 2022

What this trial tests

Phase 3 trial testing Apixaban in Atrial Fibrillation in 108 participants. Completed in 31 July 2022.

Timeline

20 June 2017

Primary endpoint
31 July 2022

31 July 2022

Quick facts

Lead sponsor	Atrial Fibrillation Network
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	108
Start date	20 June 2017
Primary completion	31 July 2022
Estimated completion	31 July 2022
Sites	1 location across Germany

Drugs / interventions tested

Apixaban (apixaban) — full drug profile →
Phenprocoumon — full drug profile →

Conditions studied

Atrial Fibrillation — all drugs for Atrial Fibrillation →
End-stage Kidney Disease — all drugs for End-stage Kidney Disease →

Sponsor

Atrial Fibrillation Network

Who can join

18 and older, any sex, with Atrial Fibrillation or End-stage Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Study is an open-labeled, randomized controlled trial, phase IIIb. Its objective is to assess the safety of the factor Xa inhibitor apixaban versus the vitamin-K antagonist (VKA) phenprocoumon in patients with NVAF and ESKD on hemodialysis. The safety will be assessed by means of the incidence of major and clinically relevant, non-major bleeding on anticoagulation.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.
Steffel J, Collins R, Antz M, Cornu P, et al · · 2021 · cited 670× · PMID 33895845 · DOI 10.1093/europace/euab065
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.
Byon W, Garonzik S, Boyd RA, Frost CE. · · 2019 · cited 215× · PMID 31089975 · DOI 10.1007/s40262-019-00775-z
Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Turakhia MP, Blankestijn PJ, Carrero JJ, Clase CM, et al · · 2018 · cited 195× · PMID 29522134 · DOI 10.1093/eurheartj/ehy060
Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline.
Klijn CJ, Paciaroni M, Berge E, Korompoki E, et al · · 2019 · cited 135× · PMID 31984228 · DOI 10.1177/2396987319841187
Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial.
De Vriese AS, Caluwé R, Caluwé R, Van Der Meersch H, et al · · 2021 · cited 125× · PMID 33753537 · DOI 10.1681/asn.2020111566
A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study.
Reinecke H, Engelbertz C, Bauersachs R, Breithardt G, et al · · 2023 · cited 122× · PMID 36335915 · DOI 10.1161/circulationaha.122.062779
Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation.
Mavrakanas TA, Mavrakanas TA, Garlo K, Charytan DM. · · 2020 · cited 66× · PMID 32444398 · DOI 10.2215/cjn.11650919
Role of direct oral anticoagulants in patients with kidney disease.
Derebail VK, Rheault MN, Kerlin BA. · · 2020 · cited 38× · PMID 32107019 · DOI 10.1016/j.kint.2019.11.027

Verify or expand the search:

Other trials of Apixaban

Trials testing the same drug.

NCT06953726 — Comparing the Safety and Efficacy of Apixaban and Rivaroxaban · Phase 4 · not yet recruiting
NCT07493304 — Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Canc · Phase 3 · not yet recruiting
NCT07521332 — Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis · Phase 4 · recruiting
NCT07160686 — Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment · Phase 3 · not yet recruiting
NCT07404345 — Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dy · Phase 4 · not yet recruiting

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting

Other Atrial Fibrillation Network trials

Trials by the same sponsor.

NCT07380932 — Catheter Ablation for AF in Patients With Severe Mitral Regurgitation After Successful Transcatheter Mitral-Valve Repair · NA · not yet recruiting
NCT04579159 — The Smartphone and Wearable Detected Atrial Arrhythmia in Older Adults Case Finding Study (Smart in OAC - AFNET 9) · NA · completed
NCT01288352 — Early Treatment of Atrial Fibrillation for Stroke Prevention Trial · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02933697 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Atrial Fibrillation Network
Last refreshed: 27 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02933697.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing